This analysis suggests TAVI in high-risk patients is cost-effective, leading to improved outcomes for high-risk patients in the Chilean healthcare system, supporting ongoing activities to fund this intervention. Further analyses should explore TAVI use in a low-risk population to better understand the implications of use in a broader patient population.
